Verve Therapeutics Newsroom

Verve Therapeutics Gains as COO Buys Shares

Seeking AlphaMay 16 11:20 ET

Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket

06:50 AM EDT, 05/16/2024 (MT Newswires) -- Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket Price: 6.65, Change: +0.42, Percent Change: +6.7

MT NewswiresMay 16 06:50 ET

Verve Therapeutics(VERV.US) Officer Buys US$475.76K in Common Stock

$Verve Therapeutics(VERV.US)$ Officer Ashe Andrew D. purchased 76,000 shares of common stock on May 14, 2024 at an average price of $6.26 for a total value of $475.76K.Source: Announcement What is sta

moomoo NewsMay 15 18:09 ET

Buy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financials

TipRanksMay 10 08:17 ET

Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week

Yahoo FinanceMay 10 07:06 ET

Express News | HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target

BenzingaMay 9 14:55 ET

Verve Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 140.19% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/03/2024 540.51% Stifel $56 → $40 Main

BenzingaMay 9 14:53 ET

RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)

TipRanksMay 9 06:55 ET

Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential

TipRanksMay 9 06:44 ET

Verve Therapeutics' Financial Outlook Threatened by CRISPR Patent Disputes

TipRanksMay 9 02:03 ET

Express News | Verve Therapeutics Inc : Jefferies Cuts Target Price to $28 From $31

ReutersMay 9 01:20 ET

Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline

TipRanksMay 8 13:55 ET

Verve Therapeutics | 10-Q: Quarterly report

Futu NewsMay 8 07:33 ET · Announcements

Verve Therapeutics 1Q Loss/Shr 59c >VERV

Verve Therapeutics 1Q Loss/Shr 59c >VERV

Dow JonesMay 8 07:06 ET

Verve Therapeutics 1Q Rev $5.7M >VERV

Verve Therapeutics 1Q Rev $5.7M >VERV

Dow JonesMay 8 07:06 ET

Express News | Verve Therapeutics Inc - First Patient Dosed in Heart-2 Phase 1B Clinical Trial of Verve-102

ReutersMay 8 07:03 ET

Express News | Verve Therapeutics Inc - Verve-201 Clinical Trial Initiation on Track for Second Half of 2024

ReutersMay 8 07:03 ET

Express News | Verve Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities of $606.4 Mln; Cash Runway Into Late 2026

ReutersMay 8 07:03 ET

Express News | Verve Therapeutics Inc - Received First Milestone Payment From Eli Lilly for Collaboration on in Vivo Gene Editing Program Targeting Lipoprotein(a)

ReutersMay 8 07:03 ET

Express News | Verve Therapeutics Q1 Net Income USD -48.736 Million

ReutersMay 8 07:00 ET